Drug intelligence / Profile preview

FIN-CoV-2

Development stage: Unknown
Lead developer: Rokote Laboratories
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

FIN-CoV-2 is an intranasal COVID-19 vaccine candidate developed by Rokote Laboratories Finland Oy. It utilizes a replication-deficient adenovirus vector (Ad5) to deliver the genetic sequence of the SARS-CoV-2 spike protein directly to the mucous membranes of the respiratory tract. This approach is designed to induce both systemic immunity and local mucosal immunity (IgA), potentially blocking the virus at its point of entry and reducing transmission more effectively than intramuscular injections. The vaccine is based on research from the University of Eastern Finland and the University of Helsinki.

Other names: Rokote nasal vaccineRokote COVID-19 vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on FIN-CoV-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIN-CoV-2.

Explore the full profile